Analysts expect Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) to announce ($0.21) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Aurinia Pharmaceuticals’ earnings, with estimates ranging from ($0.29) to ($0.12). Aurinia Pharmaceuticals posted earnings of ($0.17) per share in the same quarter last year, which suggests a negative year over year growth rate of 23.5%. The company is scheduled to report its next earnings report on Tuesday, March 17th.
On average, analysts expect that Aurinia Pharmaceuticals will report full year earnings of ($0.72) per share for the current year, with EPS estimates ranging from ($0.81) to ($0.64). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.78) per share, with EPS estimates ranging from ($1.44) to ($0.30). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Thursday, November 14th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 19,483.96% and a negative return on equity of 50.79%. The business had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.05 million.
A number of brokerages have issued reports on AUPH. Oppenheimer increased their target price on shares of Aurinia Pharmaceuticals from $14.00 to $22.00 in a research report on Thursday. Bloom Burton reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 2nd. ValuEngine cut Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. Citigroup started coverage on Aurinia Pharmaceuticals in a research report on Monday, September 9th. They set an “outperform” rating and a $14.00 price target on the stock. Finally, Cantor Fitzgerald increased their price target on Aurinia Pharmaceuticals from $24.00 to $30.00 in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Aurinia Pharmaceuticals presently has an average rating of “Buy” and an average target price of $18.46.
A number of institutional investors have recently made changes to their positions in AUPH. Tower Research Capital LLC TRC increased its holdings in Aurinia Pharmaceuticals by 630.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 8,382 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 7,234 shares during the period. Benjamin F. Edwards & Company Inc. boosted its position in shares of Aurinia Pharmaceuticals by 42.9% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 10,000 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 3,000 shares in the last quarter. Toronto Dominion Bank boosted its position in shares of Aurinia Pharmaceuticals by 26.3% during the 2nd quarter. Toronto Dominion Bank now owns 12,355 shares of the biotechnology company’s stock worth $81,000 after acquiring an additional 2,575 shares in the last quarter. UBS Asset Management Americas Inc. bought a new position in Aurinia Pharmaceuticals in the second quarter valued at approximately $88,000. Finally, Patriot Financial Group Insurance Agency LLC increased its stake in Aurinia Pharmaceuticals by 29.0% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,150 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 4,300 shares during the last quarter. Hedge funds and other institutional investors own 27.00% of the company’s stock.
Shares of Aurinia Pharmaceuticals stock opened at $15.44 on Thursday. Aurinia Pharmaceuticals has a twelve month low of $3.52 and a twelve month high of $17.48. The company has a 50-day simple moving average of $6.08 and a two-hundred day simple moving average of $6.03.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
See Also: Management Fee
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.